Coherus Oncology (CHRS) Total Current Liabilities (2013 - 2026)

Coherus Oncology has reported Total Current Liabilities for 14 years, with the latest figure at $132.3 million in Q1 2026.

• Quarterly Total Current Liabilities fell 48.11% year-over-year to $132.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132.3 million (down 48.11% YoY) and the FY2025 annual result came in at $140.4 million, down 50.39% from the prior year.
• Total Current Liabilities eased to $132.3 million in Q1 2026 per CHRS's latest filing, from $140.4 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $538.3 million in Q1 2024 and troughed at $123.4 million in Q1 2023.
• A 5-year average of $247.8 million and a median of $239.7 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 336.2% in 2024, then tumbled 52.62% in 2025.
• Over 5 years, Total Current Liabilities stood at $138.7 million in 2022, then soared by 139.21% to $331.8 million in 2023, then fell by 14.71% to $283.0 million in 2024, then plunged by 50.39% to $140.4 million in 2025, then fell by 5.74% to $132.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $132.3 million, $140.4 million, and $372.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.